[go: up one dir, main page]

MX359259B - Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida. - Google Patents

Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.

Info

Publication number
MX359259B
MX359259B MX2014002492A MX2014002492A MX359259B MX 359259 B MX359259 B MX 359259B MX 2014002492 A MX2014002492 A MX 2014002492A MX 2014002492 A MX2014002492 A MX 2014002492A MX 359259 B MX359259 B MX 359259B
Authority
MX
Mexico
Prior art keywords
choline salt
inflammatory
compound
substituted cyclobutenedione
cyclobutenedione compound
Prior art date
Application number
MX2014002492A
Other languages
English (en)
Other versions
MX2014002492A (es
Inventor
Vijay Ambarkhane Ameet
Mauler Arnaud
Timpe Carsten
Baettig Urs
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014002492A publication Critical patent/MX2014002492A/es
Publication of MX359259B publication Critical patent/MX359259B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composiciones farmacéuticas sólidas de colina de la 6-cloro-3-[2-(1 -etil-propil-amino)-3,4-dioxo-ciclobut-1-enil-amin o]-2-hidroxi-N- metoxi-N-metil-bencen-sulfonamida, y formas de dosificación orales que contienen dicho compuesto, y un método para utilizar estas composiciones y formas de dosificación orales para tratar a las personas que tengan condiciones y enfermedades inflamatorias, obstructivas o alérgicas.
MX2014002492A 2011-09-02 2012-08-31 Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida. MX359259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530516P 2011-09-02 2011-09-02
PCT/IB2012/054502 WO2013030803A1 (en) 2011-09-02 2012-08-31 Choline salt of an anti - inflammatory substituted cyclobutenedione compound

Publications (2)

Publication Number Publication Date
MX2014002492A MX2014002492A (es) 2014-05-28
MX359259B true MX359259B (es) 2018-09-20

Family

ID=47116123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002492A MX359259B (es) 2011-09-02 2012-08-31 Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.

Country Status (17)

Country Link
US (1) US9018261B2 (es)
EP (2) EP2760821B1 (es)
JP (3) JP2014529621A (es)
KR (1) KR102024955B1 (es)
CN (1) CN103842330B (es)
BR (1) BR112014004963A2 (es)
CA (1) CA2846510C (es)
EA (1) EA201490552A1 (es)
ES (1) ES2655942T3 (es)
HU (1) HUE035751T2 (es)
IN (1) IN2014DN02346A (es)
MX (1) MX359259B (es)
NO (1) NO2679622T3 (es)
PL (1) PL2760821T3 (es)
PT (1) PT2760821T (es)
SI (1) SI2760821T1 (es)
WO (1) WO2013030803A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
AU2018368731A1 (en) 2017-11-16 2020-05-14 Novartis Ag Combination therapies
CN111867579B (zh) 2018-01-08 2023-11-24 凯莫森特里克斯股份有限公司 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506252A (en) 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
MX9703375A (es) 1994-11-16 1997-08-30 American Home Prod Diaminociclobuteno-3,4-dionas.
US5840764A (en) 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
WO1998033763A1 (en) 1997-01-30 1998-08-06 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
FR2815345B1 (fr) 2000-10-12 2002-12-13 Servier Lab Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0028844D0 (en) 2000-11-27 2001-01-10 Celltech Chiroscience Ltd Chemical compounds
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
US20040132694A1 (en) 2001-01-16 2004-07-08 Palovich Michael R. Il-8 receptor antagonists
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
WO2002062761A1 (en) 2001-02-07 2002-08-15 Abbott Laboratories Aminal diones as potassium channel openers
PL373510A1 (en) 2001-03-30 2005-09-05 Smithkline Beecham Corporation Methods of synthesizing phenol-containing compounds
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CN1289471C (zh) 2001-04-16 2006-12-13 先灵公司 作为cxc－趋化因子受体配体的3,4－二取代的环丁烯－1,2－二酮
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
JP2009513512A (ja) * 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
BRPI0507329A (pt) 2004-01-30 2007-07-03 Schering Corp polimorfos cristalinos de um ligante do receptor de cxc-quimiocina
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
DE102004046492A1 (de) 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsäurederivate mit antiproliferativer Wirkung
DE102005001053A1 (de) 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
JP2008530284A (ja) 2005-02-10 2008-08-07 ワッカー ケミー アクチエンゲゼルシャフト 保護されたイソシアネート基を有する粒子を含有する塗料
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
DE102005035741A1 (de) 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
KR20090028811A (ko) 2006-07-07 2009-03-19 쉐링 코포레이션 Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된 사이클로부텐-1,2-디온
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
US7691851B2 (en) 2007-03-07 2010-04-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
AU2008258588B2 (en) 2007-06-06 2011-11-10 Novartis Ag Anti -inflammatory substituted cyclobutenedione compounds
US8519168B2 (en) 2007-07-03 2013-08-27 Merck Sharp & Dohme Corp. Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
CA2694268A1 (en) 2007-07-05 2009-01-08 Schering Corporation Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
CA2706883A1 (en) 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
WO2010002418A2 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
NZ591498A (en) 2008-08-04 2012-09-28 Merck Patent Gmbh Novel phenylamino isonicotinamide compounds
BRPI0921049A2 (pt) * 2008-11-14 2017-03-28 Portola Pharm Inc composição sólida para liberação controlada de agentes ativos ionizáveis com solubilidade aquosa pobre a um ph baixo e métodos para uso da mesma
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists

Also Published As

Publication number Publication date
JP6612200B2 (ja) 2019-11-27
NO2679622T3 (es) 2018-01-20
WO2013030803A1 (en) 2013-03-07
EA201490552A1 (ru) 2014-11-28
US20140206768A1 (en) 2014-07-24
CA2846510C (en) 2019-10-22
BR112014004963A2 (pt) 2017-03-21
IN2014DN02346A (es) 2015-05-15
ES2655942T3 (es) 2018-02-22
PT2760821T (pt) 2018-01-11
SI2760821T1 (en) 2018-02-28
PL2760821T3 (pl) 2018-04-30
US9018261B2 (en) 2015-04-28
CN103842330B (zh) 2016-10-19
CN103842330A (zh) 2014-06-04
CA2846510A1 (en) 2013-03-07
KR20140059264A (ko) 2014-05-15
JP2017025081A (ja) 2017-02-02
EP2760821B1 (en) 2017-10-11
MX2014002492A (es) 2014-05-28
KR102024955B1 (ko) 2019-09-24
JP2014529621A (ja) 2014-11-13
EP3287438A1 (en) 2018-02-28
EP2760821A1 (en) 2014-08-06
JP2019001787A (ja) 2019-01-10
HUE035751T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
MX359259B (es) Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.
EA201892339A2 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
MX349159B (es) Derivados deuterados de ivacaftor.
WO2013066835A3 (en) Compounds and methods
WO2013066839A3 (en) Compounds and methods
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
WO2012094598A3 (en) Pharmaceutical compositions of iron for oral administration
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201690962A1 (ru) Составы
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
TR201901114T4 (tr) Özgün immünomodülatör ve anti inflamatuvar bileşikler.
NZ705860A (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
MX2017001620A (es) Formas cristalinas de inhibidores de glutaminasa.
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
BR112014004435A2 (pt) inibidores de quinase rock
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
EA201490223A1 (ru) Составы на основе дарунавира
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
WO2012112447A3 (en) Histone deacetylase inhibitors and methods of use thereof
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.

Legal Events

Date Code Title Description
FG Grant or registration